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Abstract
Background and objectives In people with type 2 diabetes, aggressive control of glycemia, BP, and lipids have
resulted in conflicting short-term(,5years)kidneyoutcomes.Weaimed todetermine the long-termkidneyeffects
of these interventions.
Design, setting, participants, &measurements TheAction to Control Cardiovascular Risk in Diabetes (ACCORD)
was a multifactorial intervention study in people with type 2 diabetes at high risk for cardiovascular disease
(n=10,251), to examine the effects of intensive glycemic control (hemoglobin A1c ,6.0% versus 7%–7.9%), BP
control (systolic BP ,120 mm Hg versus ,140 mm Hg) or fenofibrate versus placebo added to simvastatin on
cardiovascular events and death. The glycemia trial lasted 3.7 years and participants were followed for another
6.5 years in ACCORDION, the ACCORD Follow-On Study. The post hoc primary composite kidney outcome
was defined as incident macroalbuminuria, creatinine doubling, need for dialysis, or death by any cause. Cox
proportional hazards regression estimated the effect of each intervention on the composite outcome and
individual components. In secondaryoutcomeanalyses, competing risk regressionwasused toaccount for the risk
ofdeath in incidentkidneyoutcomes.Analyseswere adjusted for sociodemographics, randomizationgroups, and
clinical factors.
ResultsTherewere 988casesof incidentmacroalbuminuria, 954withdoublingof creatinine, 351 requiringdialysis,
and 1905 deaths. Hazard ratios (HRs) for the composite outcome with intensive glycemic, BP control, and
fenofibrate use compared with standard therapy were 0.92 (95% confidence interval [95% CI], 0.86 to 0.98), 1.16
(95%CI, 1.05 to 1.28), and1.16 (95%CI, 1.06 to 1.27).Multivariable, secondaryoutcomeanalyses showed that in the
glycemia trial, only macroalbuminuria was significantly decreased (HR, 0.68; 95% CI, 0.59 to 0.77). In the BP and
lipid trials, only creatinine doublingwas affected (HR, 1.64; 95%CI, 1.30 to 2.06 andHR, 2.00; 95%CI, 1.61 to 2.49,
respectively).
Conclusions In peoplewith type 2 diabetes at high risk for cardiovascular disease, intensive glycemic controlmay
result in a long-term reduction inmacroalbuminuria; however, intensiveBP control and fenofibratesmay increase
the risk for adverse kidney events.
Clin J Am Soc Nephrol 13: 1693–1702, 2018. doi: https://doi.org/10.2215/CJN.06200518
Introduction
Diabetic kidney disease (DKD) is the leading cause of
ESKD, resulting in an annual fiscal burden of billions to
society and a marked decrease in quality of life for the
individual (1,2). The vast majority of patients with DKD
do not develop ESKD because of the very high incidence
of death in this population (3,4). The risks for ESKD and
cardiovascular events and death increase with rising
albuminuria and declining eGFR (5,6). The reverse is
also applicable, as the presence of cardiovascular
disease increases the incidence of creatinine doubling
and ESKD (7,8). Although patients with diabetes and
cardiovascular disease are at very high risk for pro-
gressive kidney disease and death, the optimal man-
agement of these patients is still unclear.
For decades, clinical trials have sought the ideal
clinical targets for glycemic and BP control and lipid
therapies to provide reduction in kidney risk. Historic
trials led to the commonly accepted notion that
reduction in hemoglobin A1c (HbA1c) ,7% and BP
,140/90 mm Hg decrease the risk for progression of
DKD (9,10). More recent trials have examined the
kidney effects of further reductions in HbA1c to,6%–
6.5% and systolic BP to ,120 mm Hg. Although these
trials have consistently found reductions in albumin-
uria, results are conflicting with regard to creatinine
doubling and ESKD (11–15). The effect of lipid
therapies on DKD have been more consistent: statin
medications do not appear to affect DKD progression
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this high-risk population (16); fibrates have been found to
cause a rise in creatinine that is reversible with drug
withdrawal and so are felt to not increase the risk for long-
term kidney events (17–19).
The majority of these studies were conducted over a
relatively short time period. The Action to Control Car-
diovascular Risk in Diabetes (ACCORD) trial continued to
monitor consenting participants in the ACCORD follow-on
trial (ACCORDION) for several years after trial comple-
tion, for a total mean follow-up of 7.7 years. In this post hoc
follow-up study, we aimed to determine effects of intensive




The full protocol for the main ACCORD trial has been
previously published (20,21). Inclusion criteria included (1)
type 2 diabetes and HbA1c$7.5%; (2) age 40–79 years and
known cardiovascular disease; or (3) age 55–79 years with
anatomic evidence of significant atherosclerosis, albumin-
uria, left ventricular hypertrophy, or at least two risk
factors for cardiovascular disease (dyslipidemia, hyperten-
sion, obesity, or current smoker status). Exclusion criteria
included body mass index .45 kg/m2 and serum creat-
inine .132.6 mmol/L (1.5 mg/dl). Potential participants
also had to be eligible for the BP and/or lipid trials, each of
which had additional criteria as previously published
(22,23). There were 77 clinical centers in the United States
and Canada; ethics committees at each center approved the
protocol, which adhered to the Declaration of Helsinki. All
participants provided written, informed consent. The
parent ACCORD study is registered with Clinicaltrials.
gov under identifier NCT00000620. Individual deidentified
participant data including the protocols for ACCORD and
ACCORDION, the data dictionary, manual of procedures,
and forms are currently available at https://biolincc.nhlbi.
nih.gov/studies/accord/.
Study Design, Measurements, and Outcomes
The ACCORD trial was a double two-by-two factorial,
parallel treatment trial (see Figure 1) in which patients were
randomized to one of two glycemic treatment arms, with the
intensive arm targeting HbA1c,6.0% and the standard arm
targeting HbA1c 7.0%–7.9%. On the basis of eligibility criteria,
half of the participants were allotted to a lipid intervention
consisting of randomization to fenofibrate versus placebo, both
in addition to statin therapy. The other half were allotted to one
of two randomly assigned BP treatment arms,with the intensive
arm targeting systolic BP ,120 mm Hg and the standard arm
targeting systolic BP ,140 mm Hg. The ACCORD glycemia
trial lasted for a mean of 3.7 years; it was stopped early because
of the Data Safety Monitoring Board finding of excess mortality
in the intensive glucose-lowering group (24). Participants were
subsequently managed according to the standard glucose
protocol and monitored for an additional 17 months while
the BP and lipid trials were completed.
All surviving participants who could be contacted were
invited to participate in the follow-up study (ACCORDION)
for a mean period of 7.7 years (median 5.6 years) from the
time of initial randomization (see Figure 1) (25). During the
Figure 1. | Schematic of the ACCORDandACCORDION study designs and surveillance for kidney outcomes. DSMB,Data SafetyMonitoring
Board; ACCORD, Action to Control Cardiovascular Risk in Diabetes; ACCORDION, ACCORD Follow-On Study.
The presence of any CKD was common, with 37% of
participants having eGFR,60 ml/min per 1.73 m2 and/or
UACR$30 mg/mg. In those with CKD, the severity was
mild in the vast majority, with 10% having an eGFR,60
ml/min per 1.73 m2 and 5% with macroalbuminuria.
Mean follow-up for kidney-related outcomes was 7.7
(median 5.7 years) for the glycemic intervention. Among
10,139 participants with at least some follow-up surveil-
lance for kidney-related outcomes, 7076 (69%) either
experienced the primary kidney outcome during the
ACCORD trial or had assessment for kidney outcomes
during the ACCORDION post-trial follow-up. One third
(n=3410) of participants reached the primary composite
kidney outcome. There were 988 cases of incident macro-
albuminuria, 954 with doubling of creatinine, 351 partic-
ipants requiring dialysis, and 1905 deaths. Of the 3410
participants with the primary composite kidney outcome,
two thirds (n=2249) had two or more components of the
composite outcome. Because the need for dialysis was not
adjudicated, some may have been due to AKI requiring
transient dialysis. The final serum creatinine was,2.0 mg/dl
in 257 (73%) out of 351 participants self-reporting an occur-
rence of dialysis.
Figure 2, A–C illustrates the cumulative incidence for the
composite outcome, stratified by treatment groups. Table 2
displays the univariable and multivariable results for the
effects of the three treatment trials on the composite and
secondary kidney outcomes. Randomization to the inten-
sive glycemic control arm reduced the incidence of the
composite kidney outcome (hazard ratio [HR], 0.92; 95%
confidence interval [95% CI], 0.86 to 0.98) but this effect was
primarily driven by a reduction in incident macroalbumi-
nuria (SHR, 0.68; 95% CI, 0.59 to 0.77). Post hoc analysis for
“probable maintenance dialysis” in the glycemia trial
censored participants with a final serum creatinine ,2.0,
yielding a univariable SHR of 0.85 (95% CI, 0.57 to 1.28).
Randomization to intensive BP control resulted in an
increased risk for the composite kidney outcome (HR, 1.16;
95% CI, 1.05 to 1.28); however, doubling of serum creat-
inine was the only secondary outcome to be affected (SHR,
1.64; 95% CI, 1.30 to 2.06). Similar results were obtained via
randomization to fenofibrate versus placebo (HR, 1.16; 95%
CI, 1.06 to 1.27) with a strong effect from increased risk for
doubling of serum creatinine (HR, 2.00; 95% CI, 1.61 to
2.49). Post hoc analyses for the composite kidney outcome
excluding death in the definition did not significantly
change the results.
Post hoc analyses for a differential glycemic intervention
effect was marginally significant (P=0.05), whereas the test
for a differential effect in the BP or lipid trials was
significant (P=0.01). During active treatment, there was
almost no difference in incidence of the primary kidney
outcome between intensive and standard glycemic arms
(HR, 0.99; 95% CI, 0.91 to 1.06), whereas in the post-trial
follow-up, the observed incidence was reduced in intensive
arm participants (HR, 0.83; 95% CI, 0.71 to 0.97). In the BP
trial, an increased incidence of the primary kidney outcome
in the intensive versus standard arm observed during the
active trial period (HR, 1.12; 95% CI, 1.00 to 1.26) became
larger during the post-trial follow-up (HR, 1.41; 95% CI,
1.11 to 1.79). Similarly, in the lipid trial, the increased
incidence in the fibrate versus placebo arm during the
ACCORDION trial follow-up period, participants were seen 
or contacted for surveillance of cardiovascular outcomes, 
death, and dialysis. The chronicity and indications for 
dialysis were not obtained. Surveillance for deaths in the 
United States was supplemented for participants withdrawn 
or lost to follow-up using the National Death Index. Serum 
creatinine and urine albumin-to-creatinine (UACR) were 
measured centrally on two occasions, separated by approx-
imately 30 months. eGFR was calculated using the CKD 
Epidemiology Collaboration Creatinine Equation (26).
All participants from the ACCORD trial with any 
surveillance postrandomization for kidney outcomes 
were included in analyses. Participants without surveil-
lance for kidney outcomes (n=112) either died, withdrew, 
or were lost to follow-up. We defined the primary com-
posite kidney outcome as incident macroalbuminuria 
(UACR.300 mg/mg), creatinine doubling, self-reported 
need for dialysis, or death from any cause. Secondary 
outcomes included individual end points comprising the 
primary outcome. Participants with overt albuminuria 
were excluded from analyses of incident macroalbuminu-
ria but were maintained in analyses of the composite 
outcome if they sustained one of the other outcomes 
(incident doubling of creatinine or ESKD).
Statistical Analyses
All analyses used an intention-to-treat approach. The prob-
ability of reaching the composite kidney outcome was calcu-
lated using the cumulative incidence function. Cox 
proportional hazards regression estimated the effect of each 
intervention on the primary composite kidney outcome. In 
secondary outcome analyses of the individual (nonfatal) 
composite outcome components, a competing risk regression 
was used to estimate the subdistribution hazard ratio (SHR), 
which accounts for the competing risk of death (27). Multivari-
able regression analyses included baseline values for age, sex, 
ethnicity, study site, randomization to tight BP group, ran-
domization to fenofibrate group, previous cardiovascular 
event, eGFR, UACR, angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker use, HbA1c, and systolic BP as 
covariates. Estimates of treatment assignment in each subtrial 
(intensive versus standard control in BP or fibrate versus 
placebo in lipid) were performed using contrast statements in 
proportional hazards regression models.
Differential effects of treatment arm assignment during 
active treatment versus posttrial follow-up were examined 
for the primary kidney outcome using two-way interac-
tions between a time-varying indicator event occurrence 
before or after the end of the active intervention period and 
treatment arm assignment. Interaction terms were also 
explored for sex, ethnicity, and baseline CKD status (de-
fined as macroalbuminuria or eGFR,60 ml/min per 
1.73 m2). If the interaction term was significant to P,0.1, 
we performed stratified analyses. For all other analyses, we 
utilized a nominal P value of ,0.05, without correction for 
multiple testing. All analyses were performed using SAS 
version 9.4 software (SAS Institute, Cary, NC).
Results
Baseline characteristics of participants, stratified by 
randomization in the glycemia trial, are displayed in Table 1.
active phase (HR, 1.16; 95% CI, 1.05 to 1.29) became larger
during post-trial follow-up as well (HR, 1.36; 95% CI, 1.10
to 1.69).
There was evidence for effect modification by sex in the
glycemia trial for the primary composite kidney outcome
(P=0.06), incident macroalbuminuria (P=0.02), and dialysis
outcomes (P=0.04), and in the BP and lipid trials for the
primary composite kidney outcome, macroalbuminuria
and dialysis (P,0.1). There was also evidence for effect
modification by race in the BP and lipid trials for the
primary composite kidney outcome (P=0.01), doubling of
serum creatinine (P,0.01), and all-cause mortality
(P=0.01). Results of the stratified analyses are shown in
Tables 3–5.
Discussion
This long-term follow-up study of .10,000 individuals
with type 2 diabetes at high risk for cardiovascular events
provides further data against targeting intensive glycemic
and BP control or the use of fibrates in this population.
Specifically, although intensive glycemic control amelio-
rated the risk for incident macroalbuminuria, there was a
dearth of evidence to support an effect on creatinine
doubling or incident dialysis. Moreover, we found prob-
able harm from intensive BP control or fibrate use on these
kidney outcomes.
Intensive Glycemic Control
To put these findings into context, it is important to
review in-trial and long term follow-up results from the
Diabetes Control and Complications Trial (DCCT) and
United Kingdom Prospective Diabetes Study (UKPDS),
which provided clear evidence that improved glycemic
control significantly reduced the risk for progression of
both albuminuria and worsening eGFR (9,28–30). Although
these landmark studies transformed treatment of diabetes
and demonstrated an enduring effect of controlled glyce-
mia on microvascular outcomes over decades, it is impor-
tant to underscore the trial designs and characteristics of
Table 1. Characteristics of 10,139 participants of the ACCORD study at baseline according to randomization to intensive versus
standard glycemic control
Baseline Characteristicsa
Intensive Therapy Standard Therapy
N Mean6SD or N (%) N Mean6SD or N (%)
Age, yr 5074 6267 5065 6267
Women, % 5074 1959 (39%) 5065 1940 (38%)
Non-Hispanic white, % 5074 3266 (64%) 5065 3305 (65%)
Glycated hemoglobin, % 5066 8.361.1 5053 8.361.1
BP, mm Hg 5050 5046
Systolic 136617 137617
Diastolic 75611 75611





Body mass index, kg/m 5071 3266 5062 3266
Waist circumference, cm 5019 107614 5021 107614
Previous cardiovascular event, % 5074 1804 (36%) 5065 1755 (35%)
Baseline CKD status, %b 5042 5022
No CKD 3173 (63%) 3163 (63%)
Stage 1 626 (12%) 641 (13%)
Stage 2 714 (14%) 713 (14%)
Stage 3a 425 (8%) 419 (8%)
Stage 3b 98 (2%) 92 (2%)
Stage 4 6 (0.1%) 0
Baseline UACR, % 5042 5022
$30 mg/mg 1247 (25%) 1225 (24%)
$300 mg/mg 226 (5%) 241 (5%)
$1000 mg/mg 97 (2%) 99 (2%)
eGFR, ml/min per 1.73 m2b 5074 83617 5065 84617
UACR, mg/mgc 5042 13.5 [6.8, 43.8] 5022 13.6 [6.8, 44.4]
ACEI/ARB use, % 5074 3428 (68%) 5065 3445 (68.0%)
Thiazolidinedione use, % 5074 986 (19%) 5065 976 (19%)
ACCORD, Action to Control Cardiovascular Risk in Diabetes; UACR, urine albumin-to-creatinine ratio; ACEI, angiotensin-converting
enzyme inhibitor; ARB, angiotensin receptor blocker.
aIncludesallACCORDtrialparticipantswithat least somesurveillance forprimaryoutcome.DescriptionofACCORDIONstudypopulation
is available (43).
beGFRwas calculatedusing theCKDEpidemiologyCollaborationCreatinineEquation. Stage1CKD: eGFR$90ml/minper 1.73m2and
UACR$30mg/mg; stage2CKD:eGFR60–89ml/minper1.73m2andUACR$30mg/mg; stage3aCKD:eGFR45–59ml/minper1.73m2;
stage 3b CKD: eGFR 30–44 ml/min per 1.73 m2; stage 4 CKD: eGFR 15–29 ml/min per 1.73 m2.
cData are presented as median [IQR].
Figure 2. | Cumulative incidence of the primary composite kidney outcome (incident macroalbuminuria [UACR>300 mg/mg], doubling of
creatinine, incident dialysis or all-causemortality) according to randomization arm. (A) Glycemia trial (HbA1c: intensive arm <6.0% versus
standard arm 7.0%–7.9%)with the intensive arm showing reduced risk, (B) BP trial (systolic BP: intensive arm <120mmHg versus standard
arm<140mmHg)with the intensive arm showinghigher risk, and (C) lipid trial (fenofibrate versus placebo)with the fenofibrate arm showing
higher risk.
these study populations. DCCT participants had type 1
diabetes and a mean age of 26 years; HbA1c was 7% for the
intensive treatment group versus 9% for the conventional
group. The UKPDS studied older people (mean age 54
years) with type 2 diabetes but excluded congestive heart
failure or history of multiple vascular events, and HbA1c
was 7.0% in the intensive group compared with 7.9% in the
conventional group. In contrast, ACCORD trial participant
mean age was 63 years, most had a history of macro-
vascular disease, and HbA1c was 6.4% for the intensive
group versus 7.5% for the conventional group. Consider-
ation of these differences dispel much of the quandary over
the differences in findings between these distinct patient
populations.
Discrepant findings from the Action in Diabetes and
Vascular Disease: Preterax and Diamicron MR Controlled
Evaluation (ADVANCE) trial, a cohort more similar to that
of the ACCORD trial, are more difficult to explain (11,31).
Although the ADVANCE trial found that intensive glyce-
mia conveyed a decrease in incident macroalbuminuria
(HR, 0.70; 95% CI, 0.57 to 0.85), an estimate very similar to
our results, they also found a reduced risk for ESKD after a
mean of 9.9 years (HR, 0.54; 95% CI, 0.34 to 0.85). A third
trial (97% men), the Veterans Affairs Diabetes Trial
(VADT), did not find an independent effect of intensive
glycemic control on either progressive albuminuria or
decline in eGFR or ESKD (12,32); however, the intensive
control group did have a slightly greater (albeit statistically
insignificant) percent with eGFR.60 ml/min per 1.73 m2
(32). An important distinction between these three cohorts
is the difference in severity of diabetes. Participants in the
ADVANCE study had a baseline hemoglobin A1c of 7.2%
versus 8.1% and 9.4% in the ACCORD and VADT trials,
respectively (33). Only 1.5% of participants in the
ADVANCE trial required insulin at baseline, versus 35%
in the ACCORD trial and 52% in VADT.
Intensive BP Control
Randomized trials searching for the ideal BP goal for
patients with DKD have also generated inconsistent results.
Although it is broadly accepted that macro- and micro-
vascular risk is reduced with BPs ,140/90 mm Hg (34,35),
conflicting findings exist with reductions below this
threshold (14,36,37). During the ACCORD study period,
targeting a systolic BP to ,120 mm Hg yielded a reduction
in incident macroalbuminuria 4.7 years after randomiza-
tion, but only in participants with baseline microalbumi-
nuria, and had no effect on the composite outcome of
doubling of serum creatinine, elevated serum creatinine
$3.2 mg/dl, or need for dialysis (14). Our follow-up study
of these participants 7.7 years after randomization dem-
onstrates no benefit to sustained incident macroalbuminu-
ria, and more importantly, a harm to the composite kidney
outcome, predominantly carried by doubling of creatinine.
Moreover, a separate analysis of ACCORD trial data found
that in participants with baseline CKD (UACR$30 mg/mg
or eGFR,60 ml/min per 1.73 m2), randomization to
intensive BP control did not yield significant benefit to
cerebrovascular outcomes as it did in participants without
baseline CKD (38).
In line with our findings are secondary kidney outcomes
from the Systolic Blood Pressure Intervention Trial, a study
of similar design to the ACCORD BP trial, conducted in
participants without diabetes (39). Although randomiza-
tion to systolic BP ,120 mm Hg did not significantly affect
the composite or individual kidney outcomes in partici-
pants with baseline CKD, in those without baseline CKD
there was an increased risk for $30% decline in eGFR to
Table 2. Effects of intensive glycemic control, BP control, and fenofibrate on long-term kidney outcomes in 10,139 participants of the
ACCORD study
Outcome
Intensive Glycemic Control Intensive BP Control Fenofibrate Treatment
























































































































ACCORD,Action toControlCardiovascular Risk inDiabetes; HR, hazard ratio; SHR, subhazard ratio; 95%CI, 95%confidence interval;
Int, intensive; Std, standard; Feno, fenofibrate; Plac, placebo.
aMultivariable analyses are adjusted for: baseline age, sex, ethnicity, study site, randomization to tight BP group, randomization to
fenofibrate group, previous cardiovascular event, eGFR, urine albumin-to-creatinine ratio, angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker use, hemoglobin A1c, and systolic BP.
bDenominators formacroalbuminuria outcome: 4410 intensive glycemic, 4431 standard glycemic; 2065 intensive BP, 2040 standard BP;
2388 fenofibrate, 2348 placebo.
cModels for nonfatal components of the composite outcome include death as a competing risk.
dStatistically significant results.
,60 ml/min per 1.73 m2 (HR, 3.49; 95% CI, 2.44 to 5.10).
There was also a three-fold increase in AKI requiring
hospitalization in the entire cohort (P,0.001). Also in
support of our results was the lack of significant benefit of
intensive BP control to the primary outcome in the sub-
group with baseline CKD (39).
Fenofibrate
The ACCORD lipid trial and the Fenofibrate Intervention
and Event Lowering in Diabetes (FIELD) Studies have both
documented a reversible increase in serum creatinine with
fibrates over a short-term period (17,19). In a washout
substudy of FIELD participants, there was a statistically
significant smaller decline in eGFR from baseline to an
8-week postwashout visit in the fibrate versus placebo groups
(1.9 versus 6.9 ml/min per 1.73 m2, respectively) (17).
However, this change in eGFR occurred over a mean
treatment time of 5 years, calling into question the clinical
significance of this change when viewed as an annual rate of
change. The ACCORD lipid trial also found that withdrawal
of fibrate therapy resulted in a reduction in creatinine after
51 days (19). Although there are probably reversible phys-
iologic effects from fibrates on serum creatinine levels, there
may also be long-term, irreversible consequences for DKD.
Our finding that the effect of fibrates on the composite kidney
outcome became larger during the post-trial follow-up period
further substantiates this notion.
Strengths and Limitations
A problematic issue in our study was the self-report of
“need for dialysis” without adjudication or information
regarding whether this need was sustained. Because of
Table 3. Incidence of long-term kidney outcomes according to initial randomization to intensive glycemic control (hemoglobin A1c
<6.0%), stratified by sex
Outcomea
Women Men
n=3825 (1917 Intensive; 1908 Standard) n=6146 (3075 Intensive; 3071 Standard)
Event Number HR/SHR (95% CI) Event Number HR/SHR (95% CI)
Composite outcome 579 Int 1.0 (0.89 to 1.12) 1036 Int 0.88 (0.81 to 0.95)c
589 Std 1131 Std
Macroalbuminuriab 150 Int 0.83 (0.66 to 1.05) 258 Int 0.61 (0.51 to 0.71)c
170 Std 394 Std
Dialysis 67 Int 1.11 (0.76 to 1.62) 94 Int 0.83 (0.61 to 1.13)
57 Std 129 Std
HR, hazard ratio; SHR, subhazard ratio; 95% CI, 95% confidence interval; Int, intensive; Std, standard.
aHRs and 95% CIs are for fully adjusted multivariable analyses.
bDenominators for macroalbuminuria outcome among women: 1664 intensive, 1689 standard; among men: 2688 intensive, 2704
standard.
cStatistically significant results.
Table 4. Incidence of long-term kidney outcomes according to initial randomization to intensive BP control (systolic BP <120 mmHg),
stratified by sex and also by white race
Outcomea
Women Men White Race Nonwhite Race
n=2191 (1089 Intensive; 1102
Standard)
n=2425 (1219 Intensive; 1206
Standard)
n=2808 (1382 Intensive, 1426
Standard) n=3487
Event
Number HR/SHR (95% CI)
Event
Number HR/SHR (95% CI)
Event





352 Int 1.27 (1.09 to 1.49)c 417 Int 1.07 (0.94 to 1.23) 503 Int 1.11 (0.98 to 1.26) 266 Int 1.26 (1.06 to 1.51)c
300 Std 400 Std 456 Std 244 Std
Macroalbuminuriab 86 Int 0.86 (0.64 to 1.18) 126 Int, 1.04 (0.81 to 1.34) — —
89 Std 124 Std
Doubling of creatinine — — 169 Int 2.13 (1.63 to 2.77)c 72 Int 1.17 (0.84 to 1.63)
86 Std 70 Std
Dialysis 28 Int 0.90 (0.52 to 1.56) 43 Int 0.89 (0.55 to 1.45) — —
34 Std 44 Std
All-cause mortality — — 265 Int 0.92 (0.78 to 1.09) 133 Int 1.24 (0.97 to 1.59)
282 Std 114 Std
HR,hazardratio; SHR,subhazardratio; 95%CI, 95%confidence interval; Int, intensive;Std, standard;—, analysisnotperformedbecause
interaction term was not significant.
aHRs and 95% CIs are for fully adjusted multivariable analyses using contrast statements from models with participants from both
subtrials.
bDenominators formacroalbuminuria outcome amongwomen: 965 intensive, 966 standard; amongmen: 1081 intensive, 1063 standard;
among whites: 1249 intensive, 1274 standard; among nonwhites: 797 intensive, 755 standard.
cStatistically significant results.
study design constraints, we also analyzed doubling of
serum creatinine using a single rather than multiple
creatinine values. Although the in-trial protocol measured
serum creatinine every 4 months in lipid trial participants,
creatinine was only measured annually after the first year
of follow-up in BP trial participants; furthermore, in the
extension phase, it was only measured a maximum of three
other occasions over no more than five additional years.
Another limitation was the use of a single, random UACR
(40), which can result in misclassification of microalbumi-
nuria and a higher risk of a type I error (41). Strengths of the
study include the large sample size, the randomized
controlled design, and intention-to-treat analysis. In addi-
tion, the use of a competing risk approach allows for a less
biased and more easily interpreted risk assessment for
kidney outcomes, which are always associated with in-
creased risk of death (42).
In summary, this study shows a benefit of intensive
glycemic control primarily on incident macroalbuminuria,
and an increased risk of harm from intensive BP control
and fenofibrate therapy on sustained doubling of serum
creatinine. It is important to consider the effect of in-
tensive therapies on microvascular outcomes along with
macrovascular outcomes. The original ACCORD trial and
its extension phase, the ACCORDION trial, both
demonstrated a lack of benefit from intensive glycemic
control, intensive BP control, or fibrate use, on the risk for
incident cardiovascular events and death in people with
type 2 diabetes at high risk for cardiovascular disease. The
lack of substantive benefit from these interventions on
micro- and macrovascular outcomes, and now evidence of
harm on kidney outcomes, should be considered when
revising current guidelines particularly for BP control and
lipid therapies.
Acknowledgments
Wewould like to thank theparticipants andtheir families for their
participation. The Action to Control Cardiovascular Risk in Di-
abetes Study was supported by National Heart, Lung, and Blood
Institute contracts N01-HC-95178, N01-HC-95179, N01-HC-95180,
N01-HC-95181, N01-HC-95182, N01-HC-95183, N01-HC-95184,
IAA#Y1-HC-9035, andIAA#Y1-HC-1010.Other componentsof the
National Institutes of Health, including the National Institute of
Diabetes and Digestive and Kidney Diseases and the National In-
stitute on Aging contributed funding. General Clinical Research
Centers provided support at many sites. Action to Control Car-
diovascular Risk in Diabetes Follow-On Study activities were
supported by National Heart, Lung, and Blood Institute contract
HHSN268201100027C.
The contents of this article do not represent the views of the
National Institutes of Health or the US Government.
Disclosures
J.B.B. has received contracted consulting fees, paid to his
institution, and travel support from Adocia, AstraZeneca, Dex-
com, Elcelyx Therapeutics, Eli Lilly, Intarcia Therapeutics, Lex-
icon, Metavention, NovaTarg, Novo Nordisk, Sanofi, Senseonics,
and vTv Therapeutics; and grant support from AstraZeneca,
Boehringer Ingelheim, Johnson & Johnson, Lexicon, Novo Nor-
disk, Sanofi, Theracos, and vTv Therapeutics. He holds stock
options in Mellitus Health and PhaseBio and served on the board
of the AstraZeneca HealthCare Foundation. He is supported by a
grant from the National Institutes of Health (UL1TR002489).
F.I.-B. is a consultant for Novo Nordisk, Covance, Bayer, and
Sanofi and holds grants from Novo Nordisk and the National
Institutes of Health. J.C.M. received a research grant from
Abbott Laboratories to study kidney function in the ACCORD
lipid trial. A.K.M., R.J.S., C.F.P., V.P., D.L.S., L.K., and T.E.C.
have no relevant disclosures.
Table 5. Incidence of long-term kidney outcomes according to initial randomization to fenofibrate versus placebo (in addition to statin
therapy), stratified by sex
Outcomea
Women Men White Race Nonwhite Race
n=1634 (821 Fibrate,
813 Placebo)
n=3721 (1864 Fibrate, 1857
Placebo
n=3676 (1858 Fibrate, 1818
Placebo)




















284 Feno 1.32 (1.11 to 1.57)c 703 Feno 1.10 (0.99 to 1.22) 680 Feno 1.08 (0.97 to 1.20) 307 Feno 1.36 (1.15 to 1.61)c
232 Plac 647 Plac 629 Plac 250 Plac
Macroalbuminuriab 88 Feno 1.51 (1.07 to 2.14)c 212 Feno 1.01 (0.82 to 1.24) — —
57 Plac 190 Plac
Doubling of
creatinine
— — 220 Feno 1.82 (1.46 to 2.28)c 111 Feno 2.08 (1.51 to 2.86)c
121 Plac 63 Plac
Dialysis 31 Feno 1.03 (0.61 to 1.75) 67 Feno 1.12 (0.76 to 1.66) — —
31 Plac 69 Plac
All-cause mortality — — 379 Feno
416 Plac
0.88 (0.76, 1.01) 152 Feno 1.26 (1.0, 1.60)
128 Plac
HR, hazard ratio; SHR, subhazard ratio; 95% CI, 95% confidence interval; Feno, fenofibrate; Plac, placebo;—, analysis not performed
because interaction term was not significant.
aHRs and 95% CIs are for fully adjusted multivariable analyses using contrast statements from models with participants from both
subtrials.
bDenominators formacroalbuminuriaoutcomeamongwomen:709 fenofibrate, 713placebo;amongmen: 1645 fenofibrate, 1603placebo;
among whites: 1646 fenofibrate, 1587 placebo; among nonwhites: 708 fenofibrate, 729 placebo.
cStatistically significant results.
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